Reminder: Login to access new features and members-only content!

Register to be a member of our community. Its easy!

Register a new account

Already a member?

Log In here!

Donate

Did you find our content interesting or helpful? Help support the IPFD enhance health, well-being and welfare for dogs everywhere.

Jump to content
  •   Language
  • Sign Up

International Partnership for Dogs - Enhancing Dog Health, Well-Being, and Welfare - Join Us.

Progressive Retinal Atrophy rcd2 (PRA-rcd2)

Breeds

Relevance Rating: Unknown, not evaluated or no evidence for test for these breeds

General

Disease Name
Progressive Retinal Atrophy rcd2 (PRA-rcd2)
Gene Name 2
RCD2
Mutation
22 bp insertion in exon 4
Test Type
Genetic Disease/Disorder
Details
PRA rcd2 is a disease of the retina. All forms of rcd are characterised by the initial loss of rods, the retinal cells that operate during night vision, followed by the degeneration of cones, the cells in the retina that are responsible for vision in bright light/daylight. The disease effects of rcd2 are an early onset and may be detected by an opthamologist when 6 weeks old. Vision will be lost progressively, with complete blindness by 12 months.
Details 2
PRA rcd2 is a disease of the retina. All forms of rcd are characterised by the initial loss of rods, the retinal cells that operate during night vision, followed by the degeneration of cones, the cells in the retina that are responsible for vision in bright light/daylight. The disease effects of rcd2 are an early onset and may be detected by an opthamologist when 6 weeks old. Vision will be lost progressively, with complete blindness by 12 months.
Published
Kukekova, AV., Nelson, J., Kuchtey, RW., Lowe, JK., Johnson, JL., Ostrander, EA., Aguirre, GD., Acland, GM. : Linkage mapping of canine rod cone dysplasia type 2 (rcd2) to CFA7, the canine orthologue of human 1q32. Invest Ophthalmol Vis Sci 47:1210-5, 2006. Pubmed reference: 16505060. DOI: 10.1167/iovs.05-0861.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.